Section 3 of 6
Product information and disease description
298 evidence topics · 147 sources
Product description
Phase of product development
Regulatory status: Submission planned; NDA planned after VANQUISH phase 3 data expected in the second half of 2027
Launch: Anticipated about two and a half years after October 2026
Subcutaneous formulation: FDA Type C meeting and end-of-phase 2 meeting before phase 3
Subcutaneous formulation: VANQUISH phase 3 program initiation and enrollment
Subcutaneous formulation: VANQUISH extension studies and timing of a supplemental application
Oral formulation: end-of-phase 2 meeting with the FDA
Oral formulation: SUNRISE phase 3 program initiation and expected data timing
Development history: first clinical studies of each formulation
Expedited program designations
No evidence found.
Patent estate for the GLP-1 agonist program
| Subject matter | Pending applications | Issued patents | Nominal patent term |
|---|---|---|---|
| GLP-1 agonists, as of December 31, 2025 | “113” | “13” | “2042-2045” |
Product information
Generic, brand name and therapeutic class of product
Manufacturer: Viking Therapeutics
Nonproprietary name
No evidence found.
Therapeutic class: dual GLP-1 and GIP receptor agonist
“This study aimed to determine doses of VK2735, a novel glucagon‐like peptide‐1/glucose‐dependent insulinotropic polypeptide (GLP‐1/GIP) receptor dual agonist, that are effective for weight loss over 13 weeks of treatment.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Chemical class: peptide with a half-life-extending side chain
Chemical structure, molecular formula, and molecular weight
No evidence found.
Dosage forms and strengths
Subcutaneous formulation: vial and syringe, then autoinjector, in phase 3
Subcutaneous formulation: phase 3 dose strengths
Oral formulation: once-daily tablet and phase 3 dose strengths
Subcutaneous and oral formulations: contracted finished-product formats
Commercial strengths, package configuration, and national drug code
No evidence found.
Average sales price and wholesale acquisition cost
Not applicable.
American hospital formulary service (AHFS), or other drug classification
Not applicable.
Indication
Oral formulation: phase 3 populations
Proposed U.S. labeled indication
No evidence found.
Pharmacology
Mechanism of action
Dual agonist of the GLP-1 and GIP receptors
Receptor binding affinity and half-life extension
“VK2735 binds with high affinity to both the GLP‐1 receptor (IC50: 188 nM) and GIP receptor (IC50: 325 nM) (unpublished data, Viking Therapeutics, Inc.).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The VK2735 peptide incorporates the activities of both incretins and contains a side chain that imparts an extended half‐life when administered as a subcutaneous injection.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Physiological rationale for combined GLP-1 and GIP receptor activation
Selection of VK2735 from an internally developed dual agonist series
Subcutaneous formulation: peptide administered once weekly
Oral formulation: same peptide administered once daily as a tablet
Peptide sequence, structure, and oral absorption technology
No evidence found.
Pharmacodynamics
Preclinical pharmacology of the dual agonist series: diet-induced obese mice compared with semaglutide
Preclinical pharmacology of the dual agonist series: diet-induced obese mice compared with tirzepatide
Preclinical pharmacology: 8-week weight change in obese primates compared with tirzepatide
Subcutaneous formulation: liver fat after four weekly doses in the phase 1 multiple ascending dose study
Subcutaneous formulation: plasma lipids in the phase 1 multiple ascending dose study
Subcutaneous formulation: glycemic status and lipids at week 13 in the phase 2 trial
“Of the 74 participants who had prediabetes at baseline, 58 (78%) shifted to normoglycemic at Week 13 in the active treatment groups and none shifted from prediabetes to diabetes.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Lipid markers generally declined over the 13‐week study in the active treatment group” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Only total cholesterol had a p value less than 0.05 versus placebo” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Subcutaneous formulation: fasting glucose, HbA1c, and blood pressure at week 13 in the phase 2 trial
Subcutaneous formulation: weight loss persisting after the last dose in the phase 2 trial
Subcutaneous formulation: maximal effect not reached in 13 weeks
Oral formulation: satiety and appetite in the phase 1 multiple ascending dose study
Oral formulation: weight loss persisting after the last dose and with every-other-day dosing
Gastric emptying, energy intake, and body composition in humans
No evidence found.
Pharmacokinetics
Subcutaneous formulation: half-life and time to maximum concentration after single doses
Subcutaneous formulation: phase 1 pharmacokinetic summary in the sponsor presentation
Subcutaneous formulation: predictability of pharmacokinetics in the phase 1 single ascending dose study
Subcutaneous formulation: plasma levels after the last dose and the rationale for monthly dosing
Subcutaneous formulation: half-life cited for every-other-week and monthly maintenance regimens
Subcutaneous formulation: preclinical pharmacokinetics compared with tirzepatide in primates
Oral formulation: plasma exposure in preclinical models
Oral formulation: dose proportionality of exposure in the phase 1 multiple ascending dose study
Oral formulation: bioavailability, half-life, and food effect
No evidence found.
Distribution, metabolism, and elimination pathways
No evidence found.
Contraindications/Warnings/Precautions/Adverse effects
Warnings and precautions
Approved prescribing information, boxed warnings, contraindications, and REMS
Not applicable.
Subcutaneous formulation: adverse event profile in the phase 2 trial
“The AE profile of VK2735 was primarily gastrointestinal, with decreased reported frequency upon continued use.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The most common study drug‐related TEAEs were nausea (64/175 participants [36.6%]), constipation (37/175 [21.1%]), and vomiting (22/175 [12.6%]).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Subcutaneous formulation: discontinuation and serious adverse events in the phase 2 trial
“In total, 16 of 175 participants (9.1%) experienced at least one TEAE leading to withdrawal of the study drug. The most common TEAEs experienced by these participants were nausea (five participants), vomiting (four participants), diarrhea (two participants), and headache (two participants).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“A total of 8 of 175 participants (4.6%) experienced a total of 12 TESAEs.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“One participant in the 5.0 mg dose group experienced two drug‐related TESAEs, atrial fibrillation (possibly related) and dehydration (probably related), which led to study discontinuation.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Subcutaneous formulation: adverse events of special interest and treatment discontinuation by dose in the phase 2 trial
Subcutaneous formulation: gastrointestinal adverse events with a 5.0 mg starting dose
“Nausea was highest in the first week in the 15 mg dose group; this group had a 5.0 mg starting dose, rather than the 2.5 mg starting dose in all other treatment groups” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“GI AEs were generally observed early in the study and subsided over time” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Subcutaneous formulation: heart rate change at week 13 in the phase 2 trial
Subcutaneous formulation: anti-drug antibodies in the phase 2 trial
Subcutaneous formulation: gallstone obstruction and hypoglycemia in the phase 1 multiple ascending dose study
Subcutaneous formulation: tolerability with two-week titration steps and with every-other-week or monthly maintenance
Oral formulation: discontinuation and gastrointestinal adverse events in the phase 2 trial
Oral formulation: treatment discontinuation by dose in the phase 2 trial
Oral formulation: serious and drug-related adverse events by cohort in the phase 1 multiple ascending dose study
| Event, number of subjects (%) | Placebo (n=19) | 2.5 mg (n=8) | 5 mg (n=7) | 10 mg (n=6) | 20 mg (n=8) | 40 mg (n=8) | 60 mg (n=9) | 80 mg A (n=9) | 80 mg B (n=9) | 100 mg (n=9) |
|---|---|---|---|---|---|---|---|---|---|---|
| Drug related TEAEs | “11 (58%)” | “4 (50%)” | “4 (57%)” | “3 (50%)” | “4 (50%)” | “7 (88%)” | “6 (67%)” | “9 (100%)” | “7 (78%)” | “9 (100%)” |
| Serious adverse events | “0 (0%)” | “0 (0%)” | “0 (0%)” | “0 (0%)” | “0 (0%)” | “0 (0%)” | “1 (11%)” | “0 (0%)” | “0 (0%)” | “0 (0%)” |
Oral formulation: company statement on serious adverse events in the phase 1 multiple ascending dose study
Subcutaneous formulation: thyroid, pancreatitis, and calcitonin exclusion criteria in the phase 2 and phase 3 trials
Oral formulation: thyroid, pancreatitis, and calcitonin exclusion criteria in the phase 2 and phase 3 trials
Class context: boxed warning for thyroid C-cell tumors in the tirzepatide (Zepbound) prescribing information
Special populations
Subcutaneous formulation: adults with type 2 diabetes in VANQUISH-2
Oral formulation: adults with type 2 diabetes in SUNRISE-2
Subcutaneous formulation: adults with diabetes excluded from VANQUISH-1 and the phase 2 trial
“Participants with BMI > 50 kg/m” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“or with certain medical conditions, including diabetes, were not eligible.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Oral formulation: adults with diabetes excluded from SUNRISE-1
Pediatric participants: minimum age in the phase 3 trials
Pediatric participants: clinical data with either formulation
No evidence found.
Subcutaneous formulation: age range in the phase 1 study
Oral formulation: age of participants in the phase 2 trial
Hepatic impairment: exclusion criterion in the maintenance study
Renal or hepatic impairment: pharmacokinetic data with either formulation
No evidence found.
Pregnancy and contraception: requirements in the phase 1 studies
Pregnancy and lactation: clinical data with either formulation
No evidence found.
Class context: pregnancy in the tirzepatide (Zepbound) prescribing information
Subcutaneous formulation: demographic enrollment goals in VANQUISH-1
Drug/Drug, drug/disease interactions
Effects of other drugs on VK2735
Clinical drug interaction studies with either formulation
No evidence found.
Metabolic pathway of VK2735
No evidence found.
Oral formulation: effect of food or co-administered drugs on tablet absorption
No evidence found.
Class context: metabolism of tirzepatide (Zepbound)
Effects of VK2735 on other drugs
Clinical drug interaction studies with either formulation
No evidence found.
Effect of VK2735 on gastric emptying and absorption of oral medications
No evidence found.
Class context: tirzepatide (Zepbound) with insulin or an insulin secretagogue
Class context: tirzepatide (Zepbound) with oral medications and oral hormonal contraceptives
Class context: tirzepatide (Zepbound) effects on CYP enzymes, transporters, and oral contraceptive exposure
Dosing and administration
Dosage
Proposed labeled dose, titration, and dose modification
No evidence found.
Subcutaneous formulation: maintenance doses in the VANQUISH phase 3 trials
Subcutaneous formulation: titration schedule in the VANQUISH phase 3 trials
Subcutaneous formulation: rationale for the 1.25 mg starting dose
“Given that the 5 mg dose had a higher GI TEAE rate than the 10 mg dose, there does not seem to be a dose‐dependent increase in GI TEAEs if a 2.5 mg starting dose is used at the beginning of the titration phase. The clear benefit of starting below 5.0 mg and titrating up has informed the phase 3 trial design to further improve tolerability.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Subcutaneous formulation: doses and titration in the phase 2 trial
“Participants who met eligibility criteria were randomized to one of four VK2735 weekly subcutaneous injection treatment groups (2.5, 5.0, 10, or 15 mg) or the matched placebo injection group in a 1:1:1:1:1 ratio on day 1” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Subcutaneous formulation: doses in the phase 1 single and multiple ascending dose study
Subcutaneous formulation: induction doses and two-week titration in the maintenance study
Subcutaneous formulation: every-other-week and monthly maintenance regimens
Subcutaneous formulation: less frequent regimens in the VANQUISH-1 extension
Subcutaneous induction followed by oral or subcutaneous maintenance
Oral formulation: doses in the SUNRISE phase 3 trials
Oral formulation: doses and titration in the phase 2 trial
Oral formulation: down-titration from 90 mg to 30 mg daily in the phase 2 maintenance cohort
Oral formulation: doses and titration in the phase 1 multiple ascending dose study
Administration
Instructions for use, injection sites, and storage
No evidence found.
Subcutaneous formulation: once-weekly subcutaneous injection in the phase 3 trials
Subcutaneous formulation: dosing without regard to fasting in the phase 2 trial
Subcutaneous formulation: vial and syringe, then an autoinjector after a bioequivalence study
Subcutaneous formulation: autoinjector use and clinic visit frequency in the phase 3 trials
Subcutaneous formulation: vial and syringe in the maintenance study
Oral formulation: administration relative to food, water, and other oral medications
No evidence found.
Access and distribution
Commercial manufacturing and supply agreement
Commercial organization and launch preparation
Planned distribution channels: cash pay, direct-to-consumer, and direct-to-employer
Medicare coverage: GLP-1 Bridge program
Commercialization rights and partnering
Third-party payer reimbursement risk stated by the company
Specialty pharmacy or distribution network
No evidence found.
Co-prescribed/Concomitant therapies
Subcutaneous formulation: reduced-calorie diet and exercise counseling in the phase 2 trial
“All participants were encouraged to exercise for approximately 150 min per week and reduce daily intake by 500 kcal. Instructional materials were provided at Week 0 (i.e., randomization), and counseling sessions were conducted at study sites at Week 3, Week 6, and Week 9” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Subcutaneous formulation: reduced-calorie diet and exercise counseling in the VANQUISH phase 3 trials
Oral formulation: exercise and caloric intake advice in the phase 2 trial
Subcutaneous formulation: background glucose-lowering therapy permitted in VANQUISH-2
Oral formulation: background glucose-lowering therapy permitted in SUNRISE-2
Subcutaneous formulation: glucose-lowering agents excluded in VANQUISH-1
Subcutaneous formulation: prior incretin and weight-loss medications excluded
Oral formulation: prior incretin and weight-loss medications excluded
Subcutaneous formulation: prior or planned metabolic and bariatric surgery or endoscopic therapy excluded in VANQUISH-1
Effect of VK2735 on quality measures
Product-specific effect on quality measures
No evidence found.
Merit-based Incentive Payment System 2026 measure 128: body mass index screening and follow-up plan
Healthy People 2030 objective NWS-03: proportion of adults with obesity
| Field | Objective record |
|---|---|
| Objective | “Reduce the proportion of adults with obesity” |
| National baseline | “38.6” |
| National baseline definition | “percent of adults aged 20 years and over had obesity in 2013-16” |
| Most recent data | “40.2” |
| Most recent data period | “(2021-23)” |
| National target | “36.0” |
| National status | “Little or no detectable change” |
| Desired direction | “Decrease desired” |
| Data source | “National Health and Nutrition Examination Survey (NHANES), CDC/NCHS” |
Obesity quality measures in federal reporting and payment programs
“Obesity quality measures have entered various stages of testing and development, but only a select few are included in reporting and payment programs.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“One process measure for adults, "Preventive Care and Screening: Body Mass Index (BMI) Screening and Follow-Up Plan" is used in Medicare.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“No outcome or digital quality measure exists for the disease of obesity.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The general absence of quality measures for obesity means that there are no objective measures to address the quality of obesity care or its outcome.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Product comparison
Semaglutide 2.4 mg subcutaneous: STEP 1 primary endpoint at week 68
“In this double-blind trial, we enrolled 1961 adults with a body-mass index (the weight in kilograms divided by the square of the height in meters) of 30 or greater (≥27 in persons with ≥1 weight-related coexisting condition), who did not have diabetes, and randomly assigned them, in a 2:1 ratio, to 68 weeks of treatment with once-weekly subcutaneous semaglutide (at a dose of 2.4 mg) or placebo, plus lifestyle intervention.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The mean change in body weight from baseline to week 68 was -14.9% in the semaglutide group as compared with -2.4% with placebo, for an estimated treatment difference of -12.4 percentage points (95% confidence interval [CI], -13.4 to -11.5; P<0.001).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“More participants in the semaglutide group than in the placebo group discontinued treatment owing to gastrointestinal events (59 [4.5%] vs. 5 [0.8%]).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Semaglutide 7.2 mg subcutaneous: STEP UP primary endpoint at week 72
“Participants were randomly assigned (5:1:1) to receive once-weekly subcutaneous semaglutide 7·2 mg, 2·4 mg, or placebo, with a lifestyle intervention, for 72 weeks.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The mean change in bodyweight was greater with semaglutide 7·2 mg versus 2·4 mg (-18·7% [SE 0·4] vs -15·6% [0·7]; estimated treatment difference [ETD] -3·1% [95% CI -4·7 to -1·6]; p<0·0001) and with semaglutide 7·2 mg versus placebo (-18·7% [0·4] vs -3·9% [0·6]; -14·8% [-16·2 to -13·4]; p<0·0001).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Gastrointestinal adverse events were more common with semaglutide 7·2 mg (711 [70·8%] of 1004) versus 2·4 mg (123 [61·2%] of 201) or placebo (86 [42·8%] of 201), as was dysaesthesia (230 [22·9%], 12 [6·0%], and one [0·5%], respectively).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Liraglutide 3.0 mg subcutaneous: SCALE Obesity and Prediabetes coprimary endpoints at week 56
“We randomly assigned patients in a 2:1 ratio to receive once-daily subcutaneous injections of liraglutide at a dose of 3.0 mg (2487 patients) or placebo (1244 patients); both groups received counseling on lifestyle modification.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“At week 56, patients in the liraglutide group had lost a mean of 8.4±7.3 kg of body weight, and those in the placebo group had lost a mean of 2.8±6.5 kg (a difference of -5.6 kg; 95% confidence interval, -6.0 to -5.1; P<0.001, with last-observation-carried-forward imputation).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“A total of 63.2% of the patients in the liraglutide group as compared with 27.1% in the placebo group lost at least 5% of their body weight (P<0.001), and 33.1% and 10.6%, respectively, lost more than 10% of their body weight (P<0.001).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Tirzepatide subcutaneous: SURMOUNT-1 primary endpoint at week 72
“In this phase 3 double-blind, randomized, controlled trial, we assigned 2539 adults with a body-mass index (BMI; the weight in kilograms divided by the square of the height in meters) of 30 or more, or 27 or more and at least one weight-related complication, excluding diabetes, in a 1:1:1:1 ratio to receive once-weekly, subcutaneous tirzepatide (5 mg, 10 mg, or 15 mg) or placebo for 72 weeks, including a 20-week dose-escalation period.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The mean percentage change in weight at week 72 was -15.0% (95% confidence interval [CI], -15.9 to -14.2) with 5-mg weekly doses of tirzepatide, -19.5% (95% CI, -20.4 to -18.5) with 10-mg doses, and -20.9% (95% CI, -21.8 to -19.9) with 15-mg doses and -3.1% (95% CI, -4.3 to -1.9) with placebo (P<0.001 for all comparisons with placebo).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Adverse events caused treatment discontinuation in 4.3%, 7.1%, 6.2%, and 2.6% of participants receiving 5-mg, 10-mg, and 15-mg tirzepatide doses and placebo, respectively.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Tirzepatide versus semaglutide subcutaneous: SURMOUNT-5 head-to-head primary endpoint at week 72
“In this phase 3b, open-label, controlled trial, adult participants with obesity but without type 2 diabetes were randomly assigned in a 1:1 ratio to receive the maximum tolerated dose of tirzepatide (10 mg or 15 mg) or the maximum tolerated dose of semaglutide (1.7 mg or 2.4 mg) subcutaneously once weekly for 72 weeks.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“A total of 751 participants underwent randomization. The least-squares mean percent change in weight at week 72 was -20.2% (95% confidence interval [CI], -21.4 to -19.1) with tirzepatide and -13.7% (95% CI, -14.9 to -12.6) with semaglutide (P<0.001).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Retatrutide subcutaneous, investigational: TRIUMPH-1 percent change in body weight at week 80
“In this phase 3, randomized, double-blind trial, we assigned adults with obesity without diabetes to receive a once-weekly subcutaneous injection of retatrutide (at a dose of 4 mg, 9 mg, or 12 mg) or placebo for 80 weeks.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“A total of 2339 participants underwent randomization. The mean percent change in body weight in the retatrutide groups was -17.6% (4-mg dose), -23.7% (9-mg dose), and -25.0% (12-mg dose) versus -3.9% in the placebo group (differences, -19.8 and -21.0 percentage points, respectively; P<0.001 for both comparisons).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Cagrilintide-semaglutide subcutaneous, investigational: REDEFINE 1 coprimary endpoints at week 68
“A total of 3417 participants underwent randomization, with 2108 assigned to receive cagrilintide-semaglutide, 302 to receive semaglutide, 302 to receive cagrilintide, and 705 to receive placebo.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The estimated mean percent change in body weight from baseline to week 68 was -20.4% with cagrilintide-semaglutide as compared with -3.0% with placebo (estimated difference, -17.3 percentage points; 95% confidence interval, -18.1 to -16.6; P<0.001).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Gastrointestinal adverse events (affecting 79.6% in the cagrilintide-semaglutide group and 39.9% in the placebo group), including nausea, vomiting, diarrhea, constipation, or abdominal pain, were mainly transient and mild-to-moderate in severity.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Semaglutide 2.4 mg subcutaneous in type 2 diabetes: STEP 2 primary endpoint at week 68
“From June 4 to Nov 14, 2018, 1595 patients were screened, of whom 1210 were randomly assigned to semaglutide 2·4 mg (n=404), semaglutide 1·0 mg (n=403), or placebo (n=403) and included in the intention-to-treat analysis.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Estimated change in mean bodyweight from baseline to week 68 was -9·6% (SE 0·4) with semaglutide 2·4 mg vs -3·4% (0·4) with placebo. Estimated treatment difference for semaglutide 2·4 mg versus placebo was -6·2 percentage points (95% CI -7·3 to -5·2; p<0·0001).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Tirzepatide subcutaneous in type 2 diabetes: SURMOUNT-2 primary endpoint at week 72
“Adults (aged ≥18 years) with a body-mass index (BMI) of 27 kg/m2 or higher and glycated haemoglobin (HbA1c) of 7-10% (53-86 mmol/mol) were randomly assigned (1:1:1), using a computer-generated random sequence via a validated interactive web-response system, to receive either once-weekly, subcutaneous tirzepatide (10 mg or 15 mg) or placebo for 72 weeks.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Least-squares mean change in bodyweight at week 72 with tirzepatide 10 mg and 15 mg was -12·8% (SE 0·6) and -14·7% (0·5), respectively, and -3·2% (0·5) with placebo, resulting in estimated treatment differences versus placebo of -9·6% percentage points (95% CI -11·1 to -8·1) with tirzepatide 10 mg and -11·6% percentage points (-13·0 to -10·1) with tirzepatide 15 mg (all p<0·0001).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Semaglutide 2.4 mg subcutaneous: weight regain after treatment withdrawal in the STEP 1 extension
“From week 0 to week 68, mean weight loss was 17.3% (SD: 9.3%) with semaglutide and 2.0% (SD: 6.1%) with placebo. Following treatment withdrawal, semaglutide and placebo participants regained 11.6 (SD: 7.7) and 1.9 (SD: 4.8) percentage points of lost weight, respectively, by week 120, resulting in net losses of 5.6% (SD: 8.9%) and 0.1% (SD: 5.8%), respectively, from week 0 to week 120.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“One year after withdrawal of once‐weekly subcutaneous semaglutide 2.4 mg and lifestyle intervention, participants regained two‐thirds of their prior weight loss, with similar changes in cardiometabolic variables.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Tirzepatide subcutaneous: SURMOUNT-4 randomized withdrawal from week 36 to week 88
“At week 36, a total of 670 participants were randomized (1:1) to continue receiving tirzepatide (n = 335) or switch to placebo (n = 335) for 52 weeks.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The mean percent weight change from week 36 to week 88 was −5.5% with tirzepatide vs 14.0% with placebo (difference, −19.4% [95% CI, −21.2% to −17.7%]; P < .001).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The overall mean weight reduction from week 0 to 88 was 25.3% for tirzepatide and 9.9% for placebo.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Tirzepatide subcutaneous: SURMOUNT-MAINTAIN continued, reduced, or withdrawn dosing to week 112
“After completing the initial weight-loss period with once weekly subcutaneous tirzepatide at the MTD (10 mg or 15 mg), adults (aged ≥18 years) with a BMI of 30 kg/m2 and above or 27 kg/m2 and above with one or more weight-related comorbidity, and a history of at least one self-reported unsuccessful dietary effort to lose bodyweight were randomly assigned in a 3:3:2 ratio to continue tirzepatide MTD, reduce to tirzepatide 5 mg, or switch to placebo for an additional 52 weeks.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The model-based estimate percent change in bodyweight from baseline to week 112 was -21·9% (95% CI -23·5 to -20·3) with MTD” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“-16·6% (95% CI -18·0 to -15·1) with 5 mg tirzepatide (ETD -6·6 [95% CI -8·3 to -5·0]), versus -9·9% (95% CI -11·1 to -8·8) with placebo (p<0·0001 for all comparisons)” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Oral semaglutide 25 mg: OASIS 4 primary endpoint at week 64
“The participants were randomly assigned in a 2:1 ratio to receive oral semaglutide (25 mg) or placebo once daily, plus lifestyle interventions.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“A total of 205 participants were randomly assigned to receive oral semaglutide, and 102 to receive placebo. The estimated mean change in body weight from baseline to week 64 was -13.6% in the oral semaglutide group and -2.2% in the placebo group (estimated difference, -11.4 percentage points; 95% confidence interval, -13.9 to -9.0; P<0.001).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Gastrointestinal adverse events were more common with oral semaglutide than with placebo (74.0% vs. 42.2%).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Oral orforglipron: ATTAIN-1 primary endpoint at week 72
“In this phase 3, multinational, randomized, double-blind trial, we examined the safety and efficacy of once-daily orforglipron at doses of 6 mg, 12 mg, or 36 mg, as compared with placebo (assigned in a 3:3:3:4 ratio) as an adjunct to healthy diet and physical activity for 72 weeks.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“A total of 3127 patients underwent randomization. The mean change in body weight from baseline to week 72 was -7.5% (95% confidence interval [CI], -8.2 to -6.8) with 6 mg of orforglipron, -8.4% (95% CI, -9.1 to -7.7) with 12 mg of orforglipron, and -11.2% (95% CI, -12.0 to -10.4) with 36 mg of orforglipron, as compared with -2.1% (95% CI, -2.8 to -1.4) with placebo (P<0.001 for all comparisons with placebo).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Adverse events resulted in treatment discontinuation in 5.3 to 10.3% of the patients in the orforglipron groups and in 2.7% of those in the placebo group.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Oral orforglipron: ATTAIN-MAINTAIN switch from injectable incretin therapy at week 52
“Here this double-blind, placebo-controlled trial randomized participants previously treated with tirzepatide (cohort 1: N = 205) or semaglutide (cohort 2: N = 171) during the SURMOUNT-5 study to orforglipron once daily or placebo.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Cohort 1 participants who achieved body weight plateau maintained a model-based estimate (MBE) of 74.7% (s.e.m. 4.05) of body weight reduction with orforglipron compared with an MBE of 49.2% (s.e.m. 3.92) with placebo” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Cohort 2 participants who achieved body weight plateau maintained an MBE of 79.3% (s.e.m. 4.42) of body weight reduction with orforglipron compared with an MBE of 37.6% (s.e.m. 7.46) with placebo” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Trial limitations include the absence of a comparator arm involving continued use of injectable obesity-management medications and the trial’s 1-year duration.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Place of product in therapy
Disease description
Definition and etiology
Definition: World Health Organization body mass index thresholds for adults
Definition: obesity as a chronic, relapsing disease in the WHO guideline
Definition: clinical and preclinical obesity in the Lancet Diabetes and Endocrinology Commission
“The Commission defines obesity as a condition characterised by excess adiposity, with or without abnormal distribution or function of adipose tissue, and with causes that are multifactorial and still incompletely understood.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“We define clinical obesity as a chronic, systemic illness characterised by alterations in the function of tissues, organs, the entire individual, or a combination thereof, due to excess adiposity.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“We define preclinical obesity as a state of excess adiposity with preserved function of other tissues and organs and a varying, but generally increased, risk of developing clinical obesity and several other non-communicable diseases (eg, type 2 diabetes, cardiovascular disease, certain types of cancer, and mental disorders).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Definition: adiposity-based chronic disease in the AACE algorithm
Etiology: multifactorial causes and positive energy balance
“Genetic, environmental, psychological, nutritional, and metabolic factors can induce alterations of the biological mechanisms that maintain normal mass, distribution, and function of adipose tissue, thus contributing to obesity.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The accrual of body fat occurs as a function of positive energy balance, whereby the rate of appearance of macronutrients exceeds that of disappearance.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The global rise in the prevalence of obesity is driven by social and environmental factors, in particular easy access to energy-dense, heavily marketed, processed foods that are palatable and inexpensive.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Etiology: heritability and monogenic forms
“Evidence from studies of families, twins, and adopted children shows that at least 40–70% of the variation in body weight is explainable by genetic factors (heritability).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Mutations in single genes, chromosomal regions, and copy number variants can cause severe obesity, pointing to biological pathways that regulate energy intake, energy expenditure, and body weight.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In particular, disruption of genes in the leptin-melanocortin pathway alters eating behaviour by increasing hunger, decreasing satiety, activating food reward cues, and increasing the preference for dietary fat.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Etiology: obesogenic environments and biological susceptibility
Etiology: diet and environmental exposures
“Thus, habitual consumption of highly palatable and energy-dense diets predispose to excess weight gain irrespective of macronutrient content.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Beyond diet, environmental factors ranging from socioeconomic status to chemical exposures to sedentary lifestyle can confer obesity risk.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Etiology: health behaviors, stress, health conditions, and medications
Epidemiology
Incidence of Chronic weight management
United States adults: incidence of obesity, 2001 to 2017
“Among 13,888 adults followed for 115,797 PYs, the incidence of obesity in 2001–2017 was 28.1/1000 PYs (95% CI: 26.7, 29.7).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Over the periods 2001–2005, 2005–2009, and 2009–2013, the incidence of obesity was stable, but in 2013–2017 the incidence increased by 18% compared to 2009–2013 [IRR: 1.18 (95% CI: 1.06, 1.30)].” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
United States adults: incidence of obesity by race, age, education, and baseline weight status
“Blacks had higher obesity incidence [47.9/1000 PYs (95% CI: 42.7, 53.1)] than Whites [26.2/1000 PYs (95% CI: 24.6, 27.9)].” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Across race, obesity incidence was highest in young adults (20–29 y) [34.1/1000 PYs (95% CI: 31.5, 36.7)] and declined with age [age 70+ y: 18.9/1000 PYs (95% CI: 16.6, 21.8)].” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Those with overweight had an obesity risk 7 times higher than those with normal weight [62.1/1000 PYs (95% CI: 58.8, 65.3) vs. 8.8/1000 PYs (95% CI: 8.1, 9.6)].” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Those with less than high-school education had higher obesity incidence than those with education beyond high-school [39.4/1000 PYs (95% CI: 34.4, 44.4) vs. 24.7/1000 PYs (95% CI: 23.1, 26.3)].” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Framingham Heart Study: short-term and long-term risk of developing obesity
“Four-year rates of developing obesity ranged from 5% to 7% in women and 7% to 9% in men.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The long-term risks for overweight or more or obesity exceeded 50% and 25%, respectively, indicating a large public health burden.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Prevalence of Chronic weight management
United States adults: measured prevalence of obesity, August 2021 to August 2023
United States adults: measured prevalence of severe obesity, August 2021 to August 2023
United States adults: trends in obesity and severe obesity, 2013 to 2023
United States adults: overweight, obesity, and severe obesity combined
United States states and territories: self-reported prevalence of obesity, 2025
United States adults: projected prevalence of obesity and severe obesity in 2030
“The findings from our approach suggest with high predictive accuracy that by 2030 nearly 1 in 2 adults will have obesity (48.9%; 95% confidence interval [CI], 47.7 to 50.1), and the prevalence will be higher than 50% in 29 states and not below 35% in any state.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Nearly 1 in 4 adults is projected to have severe obesity by 2030 (24.2%; 95% CI, 22.9 to 25.5), and the prevalence will be higher than 25% in 25 states.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
United States adults: overweight and obesity in 2021 and forecast to 2050
“In 2021, an estimated 15·1 million (95% UI 13·5–16·8) children and young adolescents (aged 5–14 years), 21·4 million (20·2–22·6) older adolescents (aged 15–24 years), and 172 million (169–174) adults (aged ≥25 years) had overweight or obesity in the USA.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“By 2050, the total number of children and adolescents with overweight and obesity will reach 43·1 million (37·2–47·4) and the total number of adults with overweight and obesity will reach 213 million (202–221).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In 2050, in most states, a projected one in three adolescents (aged 15–24 years) and two in three adults (≥25 years) will have obesity.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Global adults: overweight and obesity in 2024
Global adults: overweight and obesity in 2021 and forecast to 2050
“In 2021, an estimated 1·00 billion (95% uncertainty interval [UI] 0·989–1·01) adult males and 1·11 billion (1·10–1·12) adult females had overweight and obesity.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“China had the largest population of adults with overweight and obesity (402 million [397–407] individuals), followed by India (180 million [167–194]) and the USA (172 million [169–174]).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Assuming the continuation of historical trends, by 2050, we forecast that the total number of adults living with overweight and obesity will reach 3·80 billion (95% UI 3·39–4·04), over half of the likely global adult population at that time.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Global adults: number with obesity in 2022, pooled population-based data
“The number of women and men with obesity in 2022 was 504 million (489–520) and 374 million (358–391), respectively, which was an increase of 377 million (360–393) and 307 million (290–324), respectively, from 1990.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The countries with the largest absolute numbers of adults with obesity in 2022 were the USA, China, and India.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Natural history, survival, and mortality
Natural history: a chronic, relapsing course requiring lifelong care
“The guidelines recognize obesity as a chronic, relapsing disease requiring lifelong care and emphasize early diagnosis and integrated, person-centered approaches combining behavioral, medical, surgical, and other interventions alongside prevention and management of comorbidities.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Natural history: regain of lost weight
“A lack of effective options for long-term weight reduction magnifies the enormity of this problem; individuals who successfully complete behavioral and dietary weight-loss programs eventually regain most of the lost weight.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The latter process explains why weight lost through changes of diet and/or lifestyle tends to be regained over time, a major obstacle to effective obesity treatment.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Natural history: defense of body weight after weight loss
“The body responds to weight loss induced by hypocaloric diets through a robust defensive mechanism, which increases hunger and the desire to eat while decreasing energy expenditure.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The equilibrium body weight is fiercely defended by the brain, regardless of whether this set point represents a so-called healthy weight or an excessive degree of body fat in people with overweight or obesity.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Natural history: progression from preclinical to clinical obesity and end-organ damage
“Clinical obesity can lead to severe end-organ damage, causing life-altering and potentially life-threatening complications (eg, heart attack, stroke, and renal failure).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Preclinical obesity is defined as excess adiposity with preserved organ and tissue function, accompanied by an increased risk of progression to clinical obesity or other non-communicable diseases.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The development of organ dysfunction and obesity complications, whether cardiometabolic or biomechanical, can arise at different levels of adiposity in different individuals.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
All-cause mortality by body mass index category: individual-participant data meta-analysis
“The HR for obesity grade 1 (BMI 30·0–<35·0 kg/m2) was 1·45, 95% CI 1·41–1·48; the HR for obesity grade 2 (35·0–<40·0 kg/m2) was 1·94, 1·87–2·01; and the HR for obesity grade 3 (40·0–<60·0 kg/m2) was 2·76, 2·60–2·92.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“For BMI over 25·0 kg/m2, mortality increased approximately log-linearly with BMI; the HR per 5 kg/m2 units higher BMI was 1·39 (1·34–1·43) in Europe, 1·29 (1·26–1·32) in North America, 1·39 (1·34–1·44) in east Asia, and 1·31 (1·27–1·35) in Australia and New Zealand.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Life expectancy: population-based cohort in the United Kingdom
“Compared with individuals of healthy weight (BMI 18·5–24·9 kg/m2), life expectancy from age 40 years was 4·2 years shorter in obese (BMI ≥30·0 kg/m2) men and 3·5 years shorter in obese women” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Most causes, including cancer, cardiovascular diseases, and respiratory diseases, had a J-shaped association with BMI, with lowest risk occurring in the range 21–25 kg/m2.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Mortality by maximum body mass index over 24 years of weight history: Framingham Heart Study
“Among 6197 participants (mean [SD] age at baseline, 62.79 [8.98] years; 55.5% female), 3478 (56.1%) died during the follow-up.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“A monotonic association was observed between maximum BMI and mortality, with increasing risks observed across obese I (BMI of 30 to <35; hazard ratio [HR], 1.27; 95% CI, 1.14-1.41) and obese II (BMI of 35 to <40; HR, 1.93; 95% CI, 1.68-2.20) categories.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Global deaths attributable to high body mass index
“High BMI accounted for 4.0 million (2.7- 5.3) deaths globally, nearly 40% of which occurred among non-obese.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“More than two-thirds of deaths related to high BMI were due to cardiovascular disease.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Pathophysiology
Energy homeostasis and the defended level of body fat
“Growing evidence suggests that obesity is a disorder of the energy homeostasis system, rather than simply arising from the passive accumulation of excess weight.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“A major area of emphasis is the science of energy homeostasis, the biological process that maintains weight stability by actively matching energy intake to energy expenditure over time.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Central nervous system regulation of appetite and adipocyte mass
“The subcortical brain regions interact with higher cortical brain areas and hormonal signals (eg, leptin and gut hormones such as GLP-1) to regulate adipocyte mass.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Dysregulation in these neural circuits can lead to an imbalance between energy intake and expenditure, promoting uncontrolled fat accumulation, weight gain, and the development of obesity.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“NTS neurons express receptors for multiple satiety peptides such as leptin, melanocortin, and GLP-1, and are key contributors to satiety control.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Gut-derived incretin hormones: GLP-1 and GIP
“GLP-1 is secreted by L-cell enteroendocrine cells in the small intestine and colon in response to intraluminal nutrients, in particular glucose and fat.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“GLP-1 further influences nutrient utilization, as do other incretin hormones, by promoting insulin secretion and inhibiting glucagon secretion.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“However, drug trials consistently demonstrate that GLP-1 receptor agonism results in significant weight loss.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“GIP, like GLP-1, is an incretin hormone though it has previously been shown to have a minimal effect on weight.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“However, combination GIP and GLP-1 agonism results in robust weight loss, potentially related to GIP’s unique alterations in adipose cell lipid cycling” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Adipose tissue expansion, inflammation, and ectopic fat
“Hence, the pathophysiology of obesity not only involves an increase in total body fat, with preferential distribution to the intra-abdominal compartment in the presence of insulin resistance, but also ectopic lipid accrual into non-adipose tissues, especially in the liver, skeletal muscle, and the pancreas.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Storing excess energy in adipocytes is associated with ischaemia and hypoxia, apoptosis, fibrosis, and a decrease in capillary density.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Consequently, obesity functions as a chronically inflamed state that originates from adipose tissue but also occurs systemically.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Insulin resistance and cardiometabolic progression
“However, a clear majority of people with obesity suffer varying degrees of insulin resistance.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“For someone with insulin resistance, the effects can be subclinical over much of their lifespan, but eventually give rise to clinical manifestations such as prediabetes, dyslipidaemia, hypertension, metabolic syndrome, and hepatic steatosis, contributing to the development of type 2 diabetes, cardiovascular disease, and metabolic dysfunction-associated steatotic liver disease (MASLD).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Mechanisms of organ dysfunction
“Obesity can directly cause organ dysfunction via several pathophysiological mechanisms, including the physical effect of increased adipose tissue mass, the presence of ectopic fat within tissues and organs, metabolic effects, inflammatory mechanisms, and psychological consequences (figure 3).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Visceral adiposity and cardiovascular risk
“There may be a 2- to 3-fold variation in the amount of VAT at any level of total or subcutaneous adiposity.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Thus, high waist circumference (WC) even in individuals with normal weight may unmask higher CVD risk because WC is an indicator of abdominal body fat, which is associated with cardiometabolic disease and CVD and is predictive of mortality.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Pathophysiological and behavioral phenotypes
“Consequently, four actionable phenotypes were established: abnormal satiation (measured by calories ingested to experience postprandial fullness), abnormal postprandial satiety (duration of fullness and measured by GE), emotional eating behavior (measured by questionnaires) and abnormal resting energy expenditure (measured by indirect calorimetry).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“This obesity-phenotype based classification aims to match a treatment to the underlying pathophysiological abnormality seen in patients with obesity.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Diagnosis
Body mass index categories for adults
| BMI category | BMI range (kg/m2) |
|---|---|
| Underweight | “Less than 18.5” |
| Healthy weight | “18.5 to less than 25” |
| Overweight | “25 to less than 30” |
| Class 1 obesity | “30 to less than 35” |
| Class 2 obesity | “35 to less than 40” |
| Class 3 obesity (severe obesity) | “40 or greater” |
Screening and confirmation of excess adiposity: ADA Standards of Care
“8.2a Screen for overweight and obesity using BMI annually. To confirm excess adiposity, additional assessments of body fat using anthropometric assessments (e.g., waist-to-hip ratio) or direct measurements (e.g., dual-energy X-ray absorptiometry, bioelectrical impedance analysis) could be considered where available/feasible.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“It is recommended that excess adiposity be confirmed by either direct measurement of body fat, where available, or at least one anthropometric criterion (e.g., waist circumference, waist-to-hip ratio, or waist-to-height ratio) in addition to BMI, using validated methods and cutoff points appropriate to age, sex, and ethnicity and particularly in individuals with BMI 25–34.9 kg/m2 and in certain populations (South Asian individuals), as these measurements better reflect metabolic disease” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Thus, although BMI is not a perfect measure of adiposity, it remains an acceptable measure for use by clinicians who may not have the resources to obtain additional measures of adiposity on all individuals.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Diagnosis of clinical obesity: Lancet Diabetes and Endocrinology Commission criteria
“To mitigate risk of both overdiagnosis and underdiagnosis of obesity, excess adiposity should be confirmed by at least one other anthropometric criterion (eg, waist circumference) or by direct fat measurement when available. However, in people with substantially high BMI levels (ie, >40 kg/m2) excess adiposity can be pragmatically assumed.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“We recommend that BMI should be used only as a surrogate measure of health risk at a population level, for epidemiological studies, or for screening purposes, rather than as an individual measure of health.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“We defined 18 criteria for the diagnosis of clinical obesity in adults (range of consensus 90–100%; table 2), plus 13 criteria in children and adolescents (range of consensus 96–100%; table 2).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“A combination of an obesity phenotype with signs, symptoms, limitations of daily activities, or any combination of these.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Complication-centric diagnosis: AACE algorithm
“(3) diagnosis: anthropometric component, (4) diagnosis: clinical component” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Emphasis is placed on optimizing health rather than just weight reduction and achieving clinical goals other than a singular focus on body mass index (ie, complication-centric care).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Waist circumference as a vital sign
“We argue that BMI alone is not sufficient to properly assess or manage the cardiometabolic risk associated with increased adiposity in adults” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“We recommend that health professionals are trained to properly perform this simple measurement and consider it as an important ‘vital sign’ in clinical practice.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Limitations of body mass index across populations
Early identification and assessment of complications by health practitioners
Clinical presentation - signs and symptoms
Respiratory symptoms: sleep-disordered breathing, breathlessness, and wheezing
“Upper airway obstruction caused directly by obesity results in development of sleep disordered breathing, which exists on a spectrum, from snoring with increased upper airways resistance, to obstructive sleep apnoea and obesity hypoventilation syndrome.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The physical effects of increased intra-abdominal and central adiposity on diaphragmatic compliance and lung function can also contribute to breathlessness, especially during periods of increased oxygen requirements such as physical activity, or during respiratory infection (including COVID-19).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Wheezing can exist as an isolated symptom or exacerbate pre-existing respiratory diseases such as asthma and COPD.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Musculoskeletal symptoms: joint pain and restricted mobility
“Osteoarthritis, particularly affecting large, weight-bearing joints such as the hips and knees, develops as a direct effect of increased body size on these joints.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Osteoarthritis compounded by excess body weight is associated with discomfort and pain, restricting mobility, which in turn contributes to further weight gain.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Cardiovascular symptoms: heart failure, atrial fibrillation, and raised blood pressure
“Chronic fatigue, lower limb edema due to impaired diastolic dysfunction- Heart Failure with Preserved Ejection Fraction - HFpEF” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Evidence in the past several years shows relatively rapid and sizeable improvements in major heart failure symptoms with drug-induced and lifestyle-induced weight loss among people with heart failure with preserved ejection fraction.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Obesity is also causally associated with atrial fibrillation, with preliminary evidence of reduced incident atrial fibrillation from large weight loss (eg, >10% of total body mass).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Metabolic signs: hyperglycemia and dyslipidemia
“In line with such interactions, many people with obesity present with raised triglycerides, surrogate evidence of excess liver fat, and often with reduced HDL cholesterol and elevated blood glucose and HbA1c concentrations.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Reproductive and urinary symptoms: menstrual disturbance, infertility, hypogonadism, and incontinence
“The clinical symptoms of these disorders are menstruation disturbances (due to impaired ovulation), hirsutism, acne, and impaired fertility.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In men, obesity is a cause of hypogonadotropic hypogonadism resulting in spermatogenesis disturbances and erectile dysfunction.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Urinary incontinence is common in women with obesity and develops due to high intra-abdominal pressure combined with pelvic floor dysfunction.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Neurological symptoms: headache, visual loss, and peripheral neuropathy
“Idiopathic intracranial hypertension, which typically presents with progressive and severe headaches, visual loss due to papilloedema, or both, is a less common but serious consequence of obesity.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Obesity can also contribute to the development of peripheral neuropathy, independent of glycaemic status.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Lymphatic and skin signs: lymphoedema and intertrigo
“Lymphoedema of the lower limbs is strongly associated with severe obesity, particularly in women, which develops due to mechanical compression of lymphatic vessels and reduced drainage, with feelings of pain, tightness, or both, resulting in decreased range of motion.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Skin-on-skin rubbing and excessive moisture damage skin, causing inflammation and rash (eg, intertrigo), which predispose skin to fungal and bacterial infections.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Functional symptoms: limitation of activities of daily living
“Obesity often generates disability that restricts routine activities of daily living, including aspects of its management, such as physical activity, meal preparation, and access to care.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Physical restrictions can limit mobility, balance, and range of motion, impairing self-care activities including personal hygiene, bathing, toileting, dressing, and skin or foot care.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Risks of falls causing injury are higher, related to poor mobility and postural stability, especially in people with class 2 or 3 obesity.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Psychological symptoms: depression and disordered eating
“Obesity at baseline increased the risk of onset of depression at follow-up (unadjusted OR, 1.55; 95% confidence interval [CI], 1.22-1.98; P < .001).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“However, depression increased the odds for developing obesity (OR, 1.58; 95% CI, 1.33-1.87; P < .001).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Social symptoms: weight stigma and discrimination
“People with obesity commonly face a pervasive, resilient form of social stigma. They are often subject to discrimination in the workplace as well as in educational and healthcare settings.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Research indicates that weight stigma can cause physical and psychological harm, and that affected individuals are less likely to receive adequate care.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Weight discrimination is reported by 19–42% of adults with higher BMI, particularly women.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Health-services professionals are a common source of weight bias, which can lead to avoidance or delay in people seeking advice from health-care professionals.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Long-term morbidity
Incidence of 18 comorbidities: systematic review and meta-analysis
“Statistically significant associations with obesity were found with the incidence of type II diabetes, all cancers except esophageal and prostate cancer, all cardiovascular diseases, asthma, gallbladder disease, osteoarthritis and chronic back pain.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Obesity defined by BMI was also most strongly associated with the incidence of type II diabetes in females (12.41 (9.03–17.06)).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Obesity-related multimorbidity: Finnish cohorts and UK Biobank
“Obesity was associated with 21 non-overlapping cardiometabolic, digestive, respiratory, neurological, musculoskeletal, and infectious diseases after Bonferroni multiple testing adjustment and ignoring HRs of less than 1·50.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Compared with healthy weight, the confounder-adjusted HR for obesity was 2·83 (95% CI 2·74–2·93; PAF 19·9% [95% CI 19·3–20·5]) for developing at least one obesity-related disease, 5·17 (4·84–5·53; 34·4% [33·2–35·5]) for two diseases, and 12·39 (9·26–16·58; 55·2% [50·9–57·5]) for complex multimorbidity.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The proportion of participants of healthy weight with complex multimorbidity by age 75 years was observed by age 55 years in participants with obesity” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Cardiovascular disease: heart failure and atrial fibrillation
“In a study of 5881 Framingham Heart Study participants, HF incidence increased by 5% in men and 7% in women for every 1-unit BMI increase after adjustment for other risk factors, and the risk of HF increased across the entire spectrum of BMI.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Recent work has also suggested that higher BMI is more strongly associated with the risk of HFpEF than with HFrEF.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Several prospective epidemiological studies demonstrate that obesity is associated with higher risk of incident coronary artery disease (CAD).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Overweight and obesity elevate the risk of AF through numerous mechanisms, including structural and electric remodeling, which contribute to development of the arrhythmogenic substrate” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Cancer: sites with sufficient evidence for excess body fatness
“Furthermore, we identified an additional eight cancers for which there is now also sufficient evidence that the absence of body fatness lowers cancer risk, including cancers of the gastric cardia, liver, gallbladder, pancreas, ovary, and thyroid, as well as multiple myeloma and meningioma.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“There was a strong dose–response relationship, with relative risks of approximately 1.5 for overweight, 2.5 for class 1 obesity, 4.5 for class 2 obesity, and 7.1 for class 3 obesity.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Knee osteoarthritis: meta-analysis of prospective studies
“The results showed that overweight and obesity were significantly associated with higher knee OA risks of 2.45 (95% CI 1.88 to 3.20, p<0.001) and 4.55 (95% CI 2.90 to 7.13, p<0.001), respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The risk of knee OA increases by 35% (95% CI 1.18 to 1.53, p<0.001) with a 5 kg/m2 increase in BMI.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Sleep-disordered breathing: prevalence in United States adults
“Obesity is a strong causal factor for sleep-disordered breathing, and because of the ongoing obesity epidemic, previous estimates of sleep-disordered breathing prevalence require updating.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The current prevalence estimates of moderate to severe sleep-disordered breathing (apnea-hypopnea index, measured as events/hour, ≥15) are 10% (95% confidence interval (CI): 7, 12) among 30–49-year-old men; 17% (95% CI: 15, 21) among 50–70-year-old men; 3% (95% CI: 2, 4) among 30–49-year-old women; and 9% (95% CI: 7, 11) among 50–70 year-old women.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Liver and kidney disease: MASLD and obesity-related glomerulopathy
“Deposition of ectopic fat in the liver among susceptible individuals can lead to the development of MASLD.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Once MASLD progresses beyond steatosis to steatohepatitis with fibrosis, there is substantial risk of cirrhosis, liver failure, and hepatocellular carcinoma.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The development of obesity-related glomerulopathy is well recognised and can lead to end-stage kidney disease.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Type 2 diabetes: progressive beta-cell dysfunction
“Individuals predisposed to glucotoxicity and lipotoxicity of β cells have a gradual decline in insulin secretion, which becomes insufficient for normal metabolism of glucose, proteins, and lipids.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Higher levels of adiposity worsen insulin resistance, increasing β-cell demand, particularly when fat is deposited ectopically in the liver and muscle.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Burden of Chronic weight management
Humanistic burden and health-related quality of life
Obesity and health-related quality of life: systematic review of reviews
“We found that in all populations, obesity was associated with significantly lower generic and obesity‐specific HRQoL.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“in population data from six countries the relationship between BMI and SF‐36 PCS was dose‐dependent, with poorer physical HRQoL occurring in those with higher BMIs, whereas MCS scores were reduced only in those with Class III obesity.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Improved HRQoL was evident after non‐surgical weight loss, but was not consistently demonstrated, even in randomized controlled trials.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Obesity and health-related quality of life: updated systematic review of reviews
“In total, eight SLRs and/or meta‐analyses published since 2017 were identified. The results consistently demonstrated a negative association between obesity and HRQoL, with some evidence suggesting poorer HRQoL in people with adverse metabolic profiles.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Notably, no SLRs on anti‐obesity medications were identified, limiting conclusions on this emerging treatment area.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Patient-reported impacts of excess weight in qualitative interviews
“Participants consistently reported that excess weight limited physical activity and comfort, energy/stamina and self‐confidence/self‐esteem. Impacts on emotional, social and sexual functioning, as well as productivity and overall health, were also reported.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
SF-12 physical and mental component scores by BMI class in U.S. adults
“Higher BMI was associated with significantly lower scores on both SF‐12 PCS and MCS (Table 3). The median PCS score was 55.86 for NW respondents, while respondents with OW, C1, C2 and C3 obesity had a median PCS score of 54.52, 52.83, 51.28, and 47.21, respectively (p < 0.001). The median MCS score for respondents who were NW, OW, C1, C2, and C3 obesity was 54.74, 54.96, 54.59, 54.20, and 52.41, respectively (p < 0.001) (Table 3).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The proportion of respondents who reported an inability to work increased significantly (p < 0.001) with increasing BMI category (NW: 10.3%; OW: 11.2%; C1: 14.6%; C2: 17.8%; C3: 26.9%) (Table 3).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
SF-36v2, work productivity, and patient activation by BMI class in the National Health and Wellness Survey
“In the overall population of 69,742 adult respondents with BMI ≥18.5kg/m2, a lower proportion of older adults were classified as class 2/3 obesity than those <65y (Table 1)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Overall, as BMI increased people had greater negative effects on HRQoL, felt less involved with and in control of their healthcare, and had greater work productivity and activity impairments. The largest declines were generally observed between class 2 and 3 obesity categories.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“People with T2DM and obesity tended to have greater declines in physical functioning and more work and activity impairments than people with obesity without T2DM.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Utility decrement per unit of BMI used in the ICER model
Weight stigma, bias, and patient-reported experience of care
Change in physical functioning and weight-related quality of life with a GLP-1 receptor agonist
“At Week 68, a greater proportion of participants treated with semaglutide 2.4 mg than with placebo reached meaningful within-person change (MWPC) thresholds for IWQOL-Lite-CT Physical Function scores in STEP 1 (51.8% vs. 28.3%; p < 0.0001) and STEP 2 (39.6% vs. 29.5%; p = 0.0083)” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Semaglutide 2.4 mg significantly improved physical functioning, with greater proportions of participants achieving MWPC compared with placebo, and showed beneficial effects on WRQOL and HRQOL beyond physical functioning.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Economic burden and healthcare resource utilization
Excess annual medical expenditures associated with obesity in U.S. adults
“Over 30 units of BMI, each one-unit BMI increase was associated with an additional cost of $253 (95% CI $167-$347) per person. Among adults, obesity was associated with $1,861 (95% CI $1,656-$2,053) excess annual medical costs per person, accounting for $172.74 billion (95% CI $153.70-$190.61) of annual expenditures. Severe obesity was associated with excess costs of $3,097 (95% CI $2,777-$3,413) per adult.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“We estimated continuous BMI-related health care expenditures using data from the Medical Expenditure Panel Survey (MEPS) 2011–2016 for 175,726 respondents.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Costs are reported in $US 2019.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Causal estimate of medical costs due to obesity by payer and obesity class
“Adults with obesity in the United States compared with those with normal weight experienced higher annual medical care costs by $2,505 or 100%, with costs increasing significantly with class of obesity, from 68.4% for class 1 to 233.6% for class 3. The effects of obesity raised costs in every category of care: inpatient, outpatient, and prescription drugs. Increases in medical expenditures due to obesity were higher for adults covered by public health insurance programs ($2,868) than for those having private health insurance ($2,058). In 2016, the aggregate medical cost due to obesity among adults in the United States was $260.6 billion.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The expenditure estimates were obtained from 2-part models of instrumental variables in which the respondent’s body mass index (BMI) was instrumented using the BMI of their biological child.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Annual health care expenditures by BMI class in U.S. national survey data
“Healthcare expenditures, adjusted to the 2019 consumer price index, significantly increased with increasing BMI category (Table 2). The average total annual expenditures among respondents with C3 obesity were 60% higher than for NW respondents ($9212 vs. $5,236, respectively; p < 0.001). Also, the average annual prescription drug expenditures were more than double for respondents with C3 obesity compared to NW respondents ($2954 vs. $1,232, respectively; p < 0.001). Annual expenditures were driven largely by inpatient and pharmacy costs, which increased with increasing BMI (Table 2).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Compared to NW respondents (1.71 days per 6 months), the respondents in all the other BMI categories missed significantly more days of work due to illness or injury (OW: 2.30; C1: 2.47; C2: 2.66, C3: 2.92 days per 6 months; p < 0.001).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Work loss and indirect costs to employers by BMI class
“719,482 employees (normal weight: 106,631, overweight: 230,637, obesity class 1: 185,850, obesity class 2: 101,909, obesity class 3: 94,455) were included. Outcomes increased with each higher BMI category for the mean number of absence hours ([in order of BMI category]: 262, 273, 285, 290, 304) and percentage of employees with a claim (STD: 6.8%, 7.6%, 9.7%, 11.7%, 17.0%; LTD: 0.4%, 0.4%, 0.5%, 0.6%, 0.8%; WC: 2.7%, 2.8%, 3.4%, 3.6%, 3.5%). Estimated costs to the employer associated with absenteeism, STD, LTD, and WC were $1,036, $611, $38, and $95 higher per year (respectively) in the obesity class 3 cohort relative to the normal weight cohort.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Estimated reduction in health care spending with weight loss
“Overall, adults with employer-sponsored insurance with a weight loss of 5% were estimated to spend a mean of $670 (95% CI, $654-$686) less on health care (8% less), and those with a weight loss of 25% spent an estimated mean of $2849 (95% CI, $2783-$2916) less on health care (34% less). Among adults with Medicare who had 1 or more comorbid conditions, a 5% weight loss was estimated to reduce spending by $1262 (95% CI, $1217-$1306) (7% less) and a 25% weight loss was estimated to reduce health care spending by a mean of $5442 (95% CI, $5254-$5629) (31% less).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Global economic impact of overweight and obesity
“The economic impact of OAO in 2019 is estimated at 2.19% of global gross domestic product (GDP) ranging on average from US$20 per capita in Africa to US$872 per capita in the Americas and from US$6 in low-income countries to US$1110 in HICs.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“If current trends continue, by 2060, the economic impacts from OAO are projected to rise to 3.29% of GDP globally.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Economic impact of Chronic weight management on families
Not applicable.
Economic impact of diagnostic testing
Not applicable.
Approaches to treatment
Current treatment options and standard of care
Lifestyle and behavioral interventions
USPSTF recommendation for intensive multicomponent behavioral interventions
Magnitude of weight loss with behavior-based interventions
High-intensity comprehensive lifestyle intervention in the AHA/ACC/TOS guideline
“Prescribe on-site, high-intensity (ie, ≥14 sessions in 6 mo) comprehensive weight loss interventions provided in individual or group sessions by a trained interventionist.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In comprehensive lifestyle interventions, overweight/obese individuals typically are prescribed a diet designed to induce an energy deficit of ≥500 kcal/d. This deficit often is sought by prescribing 1200 to 1500 kcal/d for women and 1500 to 1800 kcal/d for men.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“produce average weight losses of up to 8 kg in 6 months of frequent (ie, initially weekly) on-site treatment provided by a trained interventionist” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Nutrition, physical activity, and behavioral therapy in adults with type 2 diabetes
“Nutrition, physical activity, and behavioral therapy are recommended for people with type 2 diabetes and overweight or obesity to achieve both weight and health outcome goals.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Interventions including high frequency of counseling (≥16 sessions in 6 months) with focus on nutrition changes, physical activity, and behavioral strategies to achieve a 500–750 kcal/day energy deficit (irrespective of macronutrient composition) should be recommended for weight loss when available.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Behavioral therapy combined with GLP-1 therapy in the WHO guideline
“WHO recommends long-term GLP-1 therapies combined with intensive behavioral therapy to maximize and sustain benefits.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Both recommendations were graded conditional” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Durability of intensive lifestyle intervention in Look AHEAD
“After the first year of the intervention, ILI participants lost a mean of 8.6% of initial weight, compared with 0.7% for participants randomly assigned to a usual care group (p<.001), referred to as Diabetes Support and Education (DSE).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“When the intervention ended, ILI participants had a mean loss of 6.0%, as measured from randomization, compared to 3.5% for DSE.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Thirty-one percent of ILI and 23.9% of DSE participants gained ≥2% (p<0.001) of EOI weight, while 36.3% and 45.9% of the two groups, respectively, lost ≥2% of EOI weight (p=0.001).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
GLP-1 receptor agonists
Semaglutide injection and tablets: FDA-approved indications
Semaglutide injection: dosage escalation and maintenance dosages for weight reduction, including 7.2 mg
Semaglutide tablets: administration on an empty stomach and maintenance dosage
Semaglutide injection and tablets: boxed warning for thyroid C-cell tumors
Semaglutide tablets: FDA approval for weight management in December 2025
Semaglutide 2.4 mg subcutaneous: cardiovascular outcomes in participants without diabetes in SELECT
“A total of 17,604 patients were enrolled; 8803 were assigned to receive semaglutide and 8801 to receive placebo.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“A primary cardiovascular end-point event occurred in 569 of the 8803 patients (6.5%) in the semaglutide group and in 701 of the 8801 patients (8.0%) in the placebo group (hazard ratio, 0.80; 95% confidence interval, 0.72 to 0.90; P<0.001).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Adverse events leading to permanent discontinuation of the trial product occurred in 1461 patients (16.6%) in the semaglutide group and 718 patients (8.2%) in the placebo group (P<0.001).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Semaglutide 2.4 mg subcutaneous: two-year weight change in STEP 5
“The mean change in body weight from baseline to week 104 was −15.2% in the semaglutide group (n = 152) versus −2.6% with placebo (n = 152), for an estimated treatment difference of −12.6 %-points (95% confidence interval, −15.3 to −9.8; P < 0.0001).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Gastrointestinal adverse events, mostly mild-to-moderate, were reported more often with semaglutide than with placebo (82.2% versus 53.9%).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
American Gastroenterological Association 2022 guideline: recommendations for semaglutide 2.4 mg and liraglutide 3.0 mg
“The panel strongly recommended the use of pharmacotherapy in addition to lifestyle intervention in adults with overweight and obesity (body mass index ≥30 kg/m2, or ≥27 kg/m2 with weight-related complications) who have an inadequate response to lifestyle interventions.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The panel suggested the use of semaglutide 2.4 mg, liraglutide 3.0 mg, phentermine-topiramate ER, and naltrexone-bupropion ER (based on moderate certainty evidence), and phentermine and diethylpropion (based on low certainty evidence), for long-term management of overweight and obesity.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
American Diabetes Association 2026 Standards of Care: preferred incretin pharmacotherapy and continuation
“In people with diabetes and overweight or obesity, the preferred pharmacotherapy should be a glucagon-like peptide 1 receptor agonist or dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide 1 receptor agonist with greater weight loss efficacy (i.e., semaglutide or tirzepatide), especially considering their added weight-independent benefits.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Obesity pharmacotherapy indicated for chronic therapy should be continued beyond reaching weight loss goals to maintain the health benefits, as discontinuation often results in recurrence of weight gain and worsening or reemergence of cardiometabolic risk factors.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Clinical trials have shown that sudden discontinuation of semaglutide and tirzepatide results in weight recurrence of one-half to two-thirds of the weight loss within 1 year with reversal of cardiometabolic improvements” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
World Health Organization 2025 guideline: conditional recommendation for long-term GLP-1 therapies
“WHO recommends long-term GLP-1 therapies combined with intensive behavioral therapy to maximize and sustain benefits.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Both recommendations were graded conditional, reflecting that GLP-1 therapies-with or without behavioral therapy-are effective, but limited long-term data, cost, system readiness, equity, variability in patient priorities, and context-specific feasibility remain considerations.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Semaglutide injection and tablets: wholesale acquisition cost
| Product and package | Quoted WAC price |
|---|---|
| Tablets, 25 mg, 30 tablets per bottle | “$1,349.02” |
| Injection, 2.4 mg dose, 4-pen package | “$1,349.02” |
| Wegovy HD injection, 7.2 mg dose, 4-pen package | “$1,349.02” |
Semaglutide injection and tablets: list price reduction effective January 2027
Liraglutide and semaglutide: average wholesale price and National Average Drug Acquisition Cost
| Medication | Typical adult maintenance dose | AWP for 30-day supply | NADAC for 30-day supply |
|---|---|---|---|
| Liraglutide | “3 mg daily”View highlighted excerpt for this quote | “$1,619”View highlighted excerpt for this quote | “$1,303”View highlighted excerpt for this quote |
| Semaglutide | “2.4 mg once weekly”View highlighted excerpt for this quote | “$1,619”View highlighted excerpt for this quote | “$1,302”View highlighted excerpt for this quote |
Dual GIP and GLP-1 receptor agonists
Tirzepatide: FDA-approved indications
Tirzepatide: dosage escalation and maintenance dosages
Tirzepatide: three-year weight change and progression to type 2 diabetes in participants with prediabetes
“At 176 weeks, the mean percent change in body weight among the participants who received tirzepatide was -12.3% with the 5-mg dose, -18.7% with the 10-mg dose, and -19.7% with the 15-mg dose, as compared with -1.3% among those who received placebo (P<0.001 for all comparisons with placebo).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Fewer participants received a diagnosis of type 2 diabetes in the tirzepatide groups than in the placebo group (1.3% vs. 13.3%; hazard ratio, 0.07; 95% confidence interval [CI], 0.0 to 0.1; P<0.001).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Tirzepatide: apnea-hypopnea index in moderate-to-severe obstructive sleep apnea in SURMOUNT-OSA
“In trial 1, the mean change in AHI at week 52 was −25.3 events per hour (95% confidence interval [CI], −29.3 to −21.2) with tirzepatide and −5.3 events per hour (95% CI, −9.4 to −1.1) with placebo, for an estimated treatment difference of −20.0 events per hour (95% CI, −25.8 to −14.2) (P<0.001).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In trial 2, the mean change in AHI at week 52 was −29.3 events per hour (95% CI, −33.2 to −25.4) with tirzepatide and −5.5 events per hour (95% CI, −9.9 to −1.2) with placebo, for an estimated treatment difference of −23.8 events per hour (95% CI, −29.6 to −17.9) (P<0.001).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Tirzepatide: oral hormonal contraceptive counseling in the American Diabetes Association 2026 Standards of Care
“Tirzepatide in particular may reduce the efficacy of oral hormonal contraceptives due to delayed gastric emptying, an effect that is largest after the first dose and diminishes over time.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Individuals using oral hormonal contraceptives should switch to a nonoral contraceptive method or add a barrier method of contraception for 4 weeks after initiation and for 4 weeks after each dose escalation.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Tirzepatide: self-pay price for the KwikPen and single-dose vial
Tirzepatide: average wholesale price and National Average Drug Acquisition Cost
| Medication | Typical adult maintenance dose | AWP for 30-day supply | NADAC for 30-day supply |
|---|---|---|---|
| Tirzepatide | “5, 10, or 15 mg once weekly”View highlighted excerpt for this quote | “$1,304”View highlighted excerpt for this quote | “$1,022”View highlighted excerpt for this quote |
Oral small-molecule GLP-1 receptor agonists
Orforglipron: FDA approval in April 2026
Orforglipron: FDA-approved indication and limitation of use
Orforglipron: administration with or without food and dosage escalation
Orforglipron: dosage modification with CYP3A4 inhibitors and inducers
Orforglipron: design and treatment discontinuation in the labeled trial of adults without diabetes
Orforglipron: equivalence of trial capsule doses to approved tablet doses
Orforglipron: weight change in adults aged 65 years and older
“In ATTAIN-1 and ATTAIN-2, 616 randomized participants were ≥65 years of age.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“At Week 72, the percent change in weight from baseline among participants from ATTAIN-1 was −7.9% (95% CI: −10.0, –5.9), −11.3% (−13.4, −9.3), and −13.0% (−15.7, −10.4) with orforglipron 5.5 mg, 9 mg, and 17.2 mg, respectively, vs. −1.6% (−3.2, 0.1) with placebo (all p < 0.001)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Orforglipron: self-pay, commercial, and Medicare Part D prices
Other anti-obesity medications
AGA guideline recommendations for pharmacotherapy
“The panel strongly recommended the use of pharmacotherapy in addition to lifestyle intervention in adults with overweight and obesity (body mass index ≥30 kg/m2, or ≥27 kg/m2 with weight-related complications) who have an inadequate response to lifestyle interventions.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The panel suggested the use of semaglutide 2.4 mg, liraglutide 3.0 mg, phentermine-topiramate ER, and naltrexone-bupropion ER (based on moderate certainty evidence), and phentermine and diethylpropion (based on low certainty evidence), for long-term management of overweight and obesity.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The guideline panel suggested against the use of orlistat.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Endocrine Society guideline on medications as adjuncts to lifestyle change
Weight loss with older anti-obesity medications in the ADA Standards of Care
| Medication | Active treatment arm; weight loss from baseline | Placebo; weight loss from baseline | Trial duration (weeks) |
|---|---|---|---|
| Phentermine | “15 mg q.d.; 7.4%”View highlighted excerpt for this quote | “Placebo; 2.3%”View highlighted excerpt for this quote | “28”View highlighted excerpt for this quote |
| Phentermine/topiramate ER | “15 mg/92 mg q.d.; 9.8%”View highlighted excerpt for this quote | “Placebo; 1.2%”View highlighted excerpt for this quote | “56”View highlighted excerpt for this quote |
| Naltrexone/bupropion ER | “16 mg/180 mg b.i.d.; 5%”View highlighted excerpt for this quote | “Placebo; 1.8%”View highlighted excerpt for this quote | “56”View highlighted excerpt for this quote |
| Orlistat | “120 mg t.i.d.; 9.6%”View highlighted excerpt for this quote | “Placebo; 5.6%”View highlighted excerpt for this quote | “52”View highlighted excerpt for this quote |
Duration of approval for phentermine and other older adrenergic agents
“Phentermine and other older adrenergic agents are approved for short-term treatment (112), while all others are approved for long-term treatment (Tables 8.1 and 8.2).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“As monotherapy, phentermine is only approved for short-term use.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Phentermine plus topiramate: CONQUER primary results at week 56
“At 56 weeks, change in bodyweight was -1·4 kg (least-squares mean -1·2%, 95% CI -1·8 to -0·7), -8·1 kg (-7·8%, -8·5 to -7·1; p<0·0001), and -10·2 kg (-9·8%, -10·4 to -9·3; p<0·0001) in the patients assigned to placebo, phentermine 7·5 mg plus topiramate 46·0 mg, and phentermine 15·0 mg plus topiramate 92·0 mg, respectively.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The most common adverse events were dry mouth (24 [2%], 67 [13%], and 207 [21%] in the groups assigned to placebo, phentermine 7·5 mg plus topiramate 46·0 mg, and phentermine 15·0 mg plus topiramate 92·0 mg, respectively), paraesthesia (20 [2%], 68 [14%], and 204 [21%], respectively)” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Naltrexone plus bupropion: COR-I primary results at week 56
“Mean change in bodyweight was -1.3% (SE 0.3) in the placebo group, -6.1% (0.3) in the naltrexone 32 mg plus bupropion group (p<0.0001 vs placebo) and -5.0% (0.3) in the naltrexone 16 mg plus bupropion group (p<0.0001 vs placebo).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“870 (50%) participants completed 56 weeks of treatment (n=296; n=284; n=290, respectively)” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Metabolic and bariatric surgery
ASMBS and IFSO indications for metabolic and bariatric surgery
“Metabolic and bariatric surgery (MBS) is recommended for individuals with a body mass index (BMI) >35 kg/m2, regardless of presence, absence, or severity of co-morbidities.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“MBS should be considered for individuals with metabolic disease and BMI of 30-34.9 kg/m2.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“BMI thresholds should be adjusted in the Asian population such that a BMI > 25 kg/m2 suggests clinical obesity, and individuals with BMI > 27.5 kg/m2 should be offered MBS.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Long-term results of MBS consistently demonstrate safety and efficacy.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
ADA recommendations for metabolic surgery in type 2 diabetes
“Consider metabolic surgery as a weight and glycemic management approach in people with type 2 diabetes with BMI ≥30.0 kg/m2 (or ≥27.5 kg/m2 in Asian American individuals) who are otherwise good surgical candidates.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“People who undergo metabolic surgery should receive long-term medical and behavioral support and routine micronutrient, nutritional, and metabolic status monitoring.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Perioperative mortality and complications
“Perioperative mortality rates are typically 0.1–0.5%, similar to those for common abdominal procedures such as cholecystectomy and hysterectomy (149,150). Major complications occur in 2–6% of those undergoing metabolic surgery, which compares favorably with the rates for other commonly performed elective operations (150).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Minor complications and need for operative reintervention occur in up to 15% (149,151–153).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Long-term survival after metabolic-bariatric surgery
“In the overall population consisting 174 772 participants, metabolic-bariatric surgery was associated with a reduction in hazard rate of death of 49·2% (95% CI 46·3-51·9, p<0·0001) and median life expectancy was 6·1 years (95% CI 5·2-6·9) longer than usual care.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Limitations of current therapies
Summary: limitations of current therapies
In the STEP 1 extension, participants who stopped semaglutide 2.4 mg at week 68 regained 11.6 of 17.3 percentage points of lost weight by week 120. In SURMOUNT-4 (670 randomized participants), those switched from tirzepatide to placebo regained 14% of body weight over 52 weeks, while those who continued tirzepatide lost a further 5.5%. A 2026 meta-analysis of 37 studies (9,341 participants) estimated weight regain of 0.4 kg per month after cessation of weight management medication, with cardiometabolic markers projected to return to baseline within 1.4 years. In commercial claims, 1-year persistence among adults without diabetes was 32.3% for initiators in 2021 and 60.9% for initiators of semaglutide (Wegovy) or tirzepatide (Zepbound) in the first half of 2024; the later study states that shortage resolution “may have improved persistence rates”. In a health-system cohort, 1-year discontinuation was 64.8% in adults without type 2 diabetes. ICER states that “there are few data from clinical trials on outcomes beyond 2-3 years” and that there “remain challenges to accessing highly effective obesity medications”. In a 2025 employer survey, 49% of large employers covered GLP-1 medications for weight loss. In the ADA table of older agents, weight loss from baseline was 5% to 9.8% with active treatment and 1.2% to 5.6% with placebo; phentermine is approved only for short-term use; and metabolic surgery carries perioperative mortality of 0.1% to 0.5% with long-term follow-up by the surgical team falling to 30% at two years.
Weight regain after withdrawal of semaglutide 2.4 mg in the STEP 1 extension
“From week 0 to week 68, mean weight loss was 17.3% (SD: 9.3%) with semaglutide and 2.0% (SD: 6.1%) with placebo. Following treatment withdrawal, semaglutide and placebo participants regained 11.6 (SD: 7.7) and 1.9 (SD: 4.8) percentage points of lost weight, respectively, by week 120, resulting in net losses of 5.6% (SD: 8.9%) and 0.1% (SD: 5.8%), respectively, from week 0 to week 120.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Cardiometabolic improvements seen from week 0 to week 68 with semaglutide reverted towards baseline at week 120 for most variables.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Weight regain after withdrawal of tirzepatide in SURMOUNT-4
“After 36 weeks of open-label maximum tolerated dose of tirzepatide (10 or 15 mg), adults (n = 670) with obesity or overweight (without diabetes) experienced a mean weight reduction of 20.9%. From randomization (at week 36), those switched to placebo experienced a 14% weight regain and those continuing tirzepatide experienced an additional 5.5% weight reduction during the 52-week double-blind period.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Rate of weight regain after cessation of weight management medications
“Of the 9288 titles screened, 37 studies (63 intervention arms, 9341 participants) were included.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The average monthly rate of weight regain was 0.4 kg (95% confidence interval (CI) 0.3 to 0.5) (mixed model 0.3 kg (0.2 to 0.4) monthly v control in RCTs). All cardiometabolic markers were projected to return to baseline within 1.4 years after the cessation of WMM. Weight regain was faster after WMM than after BWMP (by 0.3 kg (0.22 to 0.34) monthly), independent of initial weight loss.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Real-world persistence and adherence in commercially insured adults without diabetes
“Overall, GLP-1 persistence was 46.3% at 180 days and 32.3% at 1 year. The highest and lowest persistence rates at 1 year were observed for semaglutide (Ozempic) at 47.1% and liraglutide (Saxenda) 19.2%, respectively. Average PDC during the 1-year assessment was 51.0% with 27.2% adherent to therapy and 11.1% switched GLP-1 drugs.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Persistence trend by year of initiation and drug shortages
“Across the index years, 1-year persistence increased from 33.2% in 2021 to 60.9% in 1H 2024.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“For tirzepatide, 1-year persistence rates in 2023 and 1H 2024 (the only years the product was available) were 64.0% and 64.8%, respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“GLP-1RA product shortage resolution may have improved persistence rates.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Discontinuation in adults with obesity without type 2 diabetes
“Patients with obesity only had a higher prevalence of discontinuation at 12 months vs those with T2D only and those with both (50.3% vs 35.8% and 34.2%).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“One-year discontinuation was significantly higher for patients without type 2 diabetes (64.8% [95% CI, 64.4%-65.2%]) compared with those with type 2 diabetes (46.5% [95% CI, 46.2%-46.9%]).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“moderate or severe incident gastrointestinal adverse events were associated with a higher hazard of discontinuation (with type 2 diabetes: HR, 1.38 [95% CI, 1.31-1.45]; without type 2 diabetes: HR, 1.19 [95% CI, 1.12-1.27]).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Discontinuation for adverse events with injectable incretin therapy
Limited long-term outcome and safety data
Access to obesity medications and comprehensive care
Employer coverage of GLP-1 medications for weight loss
Place in treatment, anticipated use, and care setting
Summary: anticipated place in treatment
VK2735 is investigational and has no approved indication. Guidelines place anti-obesity pharmacotherapy as an adjunct to lifestyle intervention: the AGA strongly recommends pharmacotherapy in addition to lifestyle intervention for adults with BMI of 30 or higher, or 27 or higher with weight-related complications, who have an inadequate response to lifestyle interventions, and the ADA names semaglutide or tirzepatide as the preferred agents for people with diabetes and overweight or obesity. The WHO guideline describes obesity as requiring “lifelong care”. The OMA and ACOFP describe family physicians as “often the first line of treatment”, and ICER expects that “much of the treatment of obesity, including prescribing medications, will be done by primary care clinicians”. Viking describes the subcutaneous formulation as suited to weight maintenance with every-other-week or monthly dosing after weekly induction, and the VANQUISH-1 extension will include these less-frequent regimens, with results anticipated in 2028. Viking describes the oral tablet as positioned to become the first oral dual GLP-1/GIP agonist to reach the market and expects many initial users of oral therapies to transition to subcutaneous administration. In a May 2024 national poll, 12% of U.S. adults reported ever taking a GLP-1 agonist and 6% reported current use.
Preferred pharmacotherapy in people with diabetes and overweight or obesity
“Obesity pharmacotherapy should be considered for people with diabetes and overweight or obesity along with lifestyle changes. Potential benefits and risks must be considered.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In people with diabetes and overweight or obesity, the preferred pharmacotherapy should be a glucagon-like peptide 1 receptor agonist or dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide 1 receptor agonist with greater weight loss efficacy (i.e., semaglutide or tirzepatide)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Obesity as a chronic disease requiring lifelong care
“The guidelines recognize obesity as a chronic, relapsing disease requiring lifelong care and emphasize early diagnosis and integrated, person-centered approaches combining behavioral, medical, surgical, and other interventions alongside prevention and management of comorbidities.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Primary care as the care setting
“Family physicians are often the first line of treatment in the healthcare setting.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Barriers that impede optimal care of patients with obesity in primary care include failure to recognize obesity as a disease, lack of accurate diagnosis, insufficient access to obesity treatment resources, inadequate training, insufficient time, lack of adequate reimbursement and the adverse impact of bias, stigma, and discrimination.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Subcutaneous formulation: manufacturer positioning for weight maintenance
Subcutaneous formulation: less-frequent dosing regimens in the VANQUISH-1 extension
Oral formulation: manufacturer positioning
Oral and subcutaneous formulations: manufacturer positioning on dosing flexibility
Use of GLP-1 agonists among U.S. adults
Heterogeneity of treatment effect
Subgroup assessment for semaglutide and tirzepatide in the ICER review
Race and ethnicity: representation and weight loss in incretin trials
Sex, age, and region: semaglutide 2.4 mg in SELECT
“Women had a greater difference in mean weight loss with semaglutide versus placebo (−11.1% (95% CI −11.56 to −10.66) versus −7.5% in men (95% CI −7.78 to −7.23); P < 0.0001).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“There was a linear relationship between age category and degree of mean weight loss, with younger age being associated with progressively greater mean weight loss, but the actual mean difference by age group is small.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Patients from Asia and of Asian race experienced slightly lower mean weight loss (estimated treatment difference with semaglutide for Asian race −7.27% (95% CI −8.09 to −6.46; P = 0.0147) and for Asia −7.30 (95% CI −7.97 to −6.62; P = 0.0016)).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Reproductive stage: tirzepatide in women in SURMOUNT-1
“In SURMOUNT‐1, significantly greater body weight reductions from baseline were observed with tirzepatide versus placebo in women in the premenopause (26% vs. 2%), perimenopause (23% vs. 3%), and postmenopause stages (23% vs. 3%; p < 0.001).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Diabetes status: tirzepatide in SURMOUNT-1, adults without diabetes
“The mean percentage change in weight at week 72 was -15.0% (95% confidence interval [CI], -15.9 to -14.2) with 5-mg weekly doses of tirzepatide, -19.5% (95% CI, -20.4 to -18.5) with 10-mg doses, and -20.9% (95% CI, -21.8 to -19.9) with 15-mg doses and -3.1% (95% CI, -4.3 to -1.9) with placebo” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Diabetes status: tirzepatide in SURMOUNT-2, adults with type 2 diabetes
Diabetes status: semaglutide 7.2 mg in STEP UP, adults without diabetes
“The mean change in bodyweight was greater with semaglutide 7·2 mg versus 2·4 mg (-18·7% [SE 0·4] vs -15·6% [0·7]; estimated treatment difference [ETD] -3·1% [95% CI -4·7 to -1·6]; p<0·0001) and with semaglutide 7·2 mg versus placebo (-18·7% [0·4] vs -3·9% [0·6]; -14·8% [-16·2 to -13·4]; p<0·0001).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Diabetes status: semaglutide 7.2 mg in STEP UP T2D, adults with type 2 diabetes
Age 65 years and older: oral orforglipron in ATTAIN-1 and ATTAIN-2
“At Week 72, the percent change in weight from baseline among participants from ATTAIN-1 was −7.9% (95% CI: −10.0, –5.9), −11.3% (−13.4, −9.3), and −13.0% (−15.7, −10.4) with orforglipron 5.5 mg, 9 mg, and 17.2 mg, respectively, vs. −1.6% (−3.2, 0.1) with placebo (all p < 0.001)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Comparable findings were observed in participants <65 years of age.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Subcutaneous formulation: BMI category change by baseline obesity class in VENTURE
Diabetes status: survival after metabolic-bariatric surgery
“In subgroup analyses, both individuals with (hazard ratio 0·409, 95% CI 0·370-0·453, p<0·0001) or without (0·704, 0·588-0·843, p<0·0001) baseline diabetes who underwent metabolic-bariatric surgery had lower rates of all-cause mortality, but the treatment effect was considerably greater for those with diabetes (between-subgroup I2 95·7%, p<0·0001).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Care management intervention strategies
Coverage criteria recommended by ICER for incretin anti-obesity medications
Step therapy and preferred formulary options
Medicare GLP-1 Bridge demonstration
BALANCE Model: negotiated prices, lifestyle support, and product eligibility
Structured behavioral programs alongside pharmacotherapy
Other product development or post-marketing obligations required by the FDA
Not applicable.
Ongoing post-approval monitoring
Not applicable.
Expected outcomes of therapy
Cardiovascular events: semaglutide 2.4 mg in SELECT
“A primary cardiovascular end-point event occurred in 569 of the 8803 patients (6.5%) in the semaglutide group and in 701 of the 8801 patients (8.0%) in the placebo group (hazard ratio, 0.80; 95% confidence interval, 0.72 to 0.90; P<0.001).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Adverse events leading to permanent discontinuation of the trial product occurred in 1461 patients (16.6%) in the semaglutide group and 718 patients (8.2%) in the placebo group (P<0.001).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Weight loss sustained to 4 years in SELECT
“In patients treated with semaglutide, weight loss continued over 65 weeks and was sustained for up to 4 years. At 208 weeks, semaglutide was associated with mean reduction in weight (−10.2%), waist circumference (−7.7 cm) and waist-to-height ratio (−6.9%) versus placebo (−1.5%, −1.3 cm and −1.0%, respectively; P < 0.0001 for all comparisons versus placebo).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Progression to type 2 diabetes: tirzepatide over 176 weeks in SURMOUNT-1
“At 176 weeks, the mean percent change in body weight among the participants who received tirzepatide was -12.3% with the 5-mg dose, -18.7% with the 10-mg dose, and -19.7% with the 15-mg dose, as compared with -1.3% among those who received placebo (P<0.001 for all comparisons with placebo).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Fewer participants received a diagnosis of type 2 diabetes in the tirzepatide groups than in the placebo group (1.3% vs. 13.3%; hazard ratio, 0.07; 95% confidence interval [CI], 0.0 to 0.1; P<0.001).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Obstructive sleep apnea: tirzepatide in SURMOUNT-OSA
“In trial 1, the mean change in AHI at week 52 was −25.3 events per hour (95% confidence interval [CI], −29.3 to −21.2) with tirzepatide and −5.3 events per hour (95% CI, −9.4 to −1.1) with placebo, for an estimated treatment difference of −20.0 events per hour (95% CI, −25.8 to −14.2) (P<0.001).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In trial 2, the mean change in AHI at week 52 was −29.3 events per hour (95% CI, −33.2 to −25.4) with tirzepatide and −5.5 events per hour (95% CI, −9.9 to −1.2) with placebo, for an estimated treatment difference of −23.8 events per hour (95% CI, −29.6 to −17.9) (P<0.001).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Heart failure with preserved ejection fraction: semaglutide 2.4 mg in STEP-HFpEF
“The mean change in the KCCQ-CSS was 16.6 points with semaglutide and 8.7 points with placebo (estimated difference, 7.8 points; 95% confidence interval [CI], 4.8 to 10.9; P<0.001), and the mean percentage change in body weight was -13.3% with semaglutide and -2.6% with placebo (estimated difference, -10.7 percentage points; 95% CI, -11.9 to -9.4; P<0.001).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The mean change in the 6-minute walk distance was 21.5 m with semaglutide and 1.2 m with placebo (estimated difference, 20.3 m; 95% CI, 8.6 to 32.1; P<0.001).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Steatohepatitis: semaglutide 2.4 mg in ESSENCE
“Resolution of steatohepatitis without worsening of fibrosis occurred in 62.9% of the 534 patients in the semaglutide group and in 34.3% of the 266 patients in the placebo group (estimated difference, 28.7 percentage points; 95% confidence interval [CI], 21.1 to 36.2; P<0.001).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“A reduction in liver fibrosis without worsening of steatohepatitis was reported in 36.8% of the patients in the semaglutide group and in 22.4% of those in the placebo group (estimated difference, 14.4 percentage points; 95% CI, 7.5 to 21.3; P<0.001).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Health care spending associated with weight loss
“In this cross-sectional study of 17 209 adults, among those with employer-sponsored insurance, adults with a baseline BMI of 30 were estimated to spend 7% less following the loss of 5% of BMI and 30% less following the loss of 25% of BMI. Similar results were found for Medicare adults.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote